Opthea (OPT) Stock Forecast, Price Target & Predictions
OPT Stock Forecast
Opthea stock forecast is as follows: an average price target of $14.00 (represents a 329.45% upside from OPT’s last price of $3.26) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OPT Price Target
The average price target for Opthea (OPT) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 329.45% upside from OPT's last price of $3.26.
OPT Analyst Ratings
According to 5 Wall Street analysts, Opthea's rating consensus is 'Buy'. The analyst rating breakdown for OPT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Opthea Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | H.C. Wainwright | $14.00 | $4.97 | 181.69% | 329.45% |
The latest Opthea stock forecast, released on Dec 08, 2022 by H.C. Wainwright company, set a price target of $14.00, which represents a 181.69% increase from the stock price at the time of the forecast ($4.97), and a 329.45% increase from OPT last price ($3.26).
Opthea Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.26 | $3.26 | $3.26 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Opthea stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Opthea's last price of $3.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 25, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 16, 2022 | Citigroup | Buy | Buy | Hold |
| Apr 26, 2022 | SVB Leerink | - | Outperform | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Opthea's last stock rating was published by H.C. Wainwright on Sep 03, 2024. The company gave OPT a "Buy" rating, the same as its previous rate.
Opthea Financial Forecast
Opthea Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | $65.54K | $62.51K | $149.71K | $52.76K |
| High Forecast | $65.54K | $62.51K | $740.29K | $52.76K |
| Low Forecast | $65.54K | $62.51K | $1.50K | $52.76K |
| # Analysts | 4 | 4 | 5 | 4 |
| Surprise % | - | - | - | - |
Opthea's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. OPT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Opthea EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 4 | 4 | 5 | 4 |
| EBITDA | - | - | - | - |
| Avg Forecast | $-65.54K | $-62.51K | $-149.71K | $-52.76K |
| High Forecast | $-65.54K | $-62.51K | $-1.50K | $-52.76K |
| Low Forecast | $-65.54K | $-62.51K | $-740.29K | $-52.76K |
| Surprise % | - | - | - | - |
undefined analysts predict OPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Opthea's previous annual EBITDA (undefined) of $NaN.
Opthea Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 4 | 4 | 5 | 4 |
| Net Income | - | - | - | - |
| Avg Forecast | $-51.22M | $181.85M | $-95.94M | $-77.83M |
| High Forecast | $-51.22M | $181.85M | $-95.94M | $-77.83M |
| Low Forecast | $-51.22M | $181.85M | $-95.94M | $-77.83M |
| Surprise % | - | - | - | - |
Opthea's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Opthea SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 4 | 4 | 5 | 4 |
| SG&A | - | - | - | - |
| Avg Forecast | $9.68M | $9.24M | $22.12M | $7.80M |
| High Forecast | $9.68M | $9.24M | $109.39M | $7.80M |
| Low Forecast | $9.68M | $9.24M | $221.80K | $7.80M |
| Surprise % | - | - | - | - |
Opthea's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to OPT last annual SG&A of $NaN (undefined).
Opthea EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 4 | 4 | 5 | 4 |
| EPS | - | - | - | - |
| Avg Forecast | $-0.64 | $2.27 | $-1.20 | $-0.97 |
| High Forecast | $-0.64 | $2.27 | $-1.20 | $-0.97 |
| Low Forecast | $-0.64 | $2.27 | $-1.20 | $-0.97 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Opthea's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OPT previous annual EPS of $NaN (undefined).
Opthea Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.00 | $8.75 | 775.00% | Buy |
| AVTE | Aerovate Therapeutics | $2.53 | $13.00 | 413.83% | Hold |
| MOLN | Molecular Partners | $5.83 | $29.00 | 397.43% | Buy |
| OPT | Opthea | $3.26 | $14.00 | 329.45% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.53 | $6.00 | 292.16% | Buy |
| ACRV | Acrivon Therapeutics | $6.27 | $21.83 | 248.17% | Buy |
| RZLT | Rezolute | $4.87 | $13.50 | 177.21% | Buy |
| MLYS | Mineralys Therapeutics | $11.40 | $30.00 | 163.16% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| ADAG | Adagene | $2.24 | $5.00 | 123.21% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |